Form 4: 4D Molecular Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc., sold 584 shares of common stock on September 1, 2026 for $14.00 per share.
Summary
- Option exercise/conversion: acquired 584 Common Stock at $6.49 ($3,790) on September 1, 2026; holds 9,201 after (Direct).
- Open-market sale: disposed of 584 Common Stock at $14.00 ($8,176) on September 1, 2026; holds 8,617 after (Direct).
- Option exercise/conversion: disposed of 584 Stock Option (Right to Buy) on September 1, 2026; holds 2,959 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $8,176 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Scott Bizily — Officer (Chief Legal Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 584 | $6 | $3.8K | 9,201 |
| 2026-09-01 | Open-market sale | Common Stock | 584 | $14 | $8.2K | 8,617 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 584 | — | — | 2,959 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (584 shares) |
| 2026-09-01 | Open-market sale (584 shares) |
| 2026-09-01 | Option exercise/conversion (584 shares) |
Keywords
insider transaction, Form 4, FDMT, 4D Molecular Therapeutics, Inc., bearish, Scott Bizily
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.